Informations générales (source: ClinicalTrials.gov)
Treating Atopic Dermatitis With Abrocitinib and Its Impact in Real Life: An Observational Cohort Study To Describe the Effectiveness of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis. (ADAIR)
Observational
Pfizer (Voir sur ClinicalTrials)
mars 2023
mai 2027
14 mai 2025
The purpose of this study is to learn about the safety and effects of Abrocitinib in the
real-life clinical setting given for the treatment of moderate to severe atopic
dermatitis. Atopic dermatitis, or AD, is a long-lasting disease that causes inflammation,
redness, and irritation of the skin.
This study is seeking participant who are older than 18 years with moderate-to-severe
chronic AD. Participants must have no underlying medical conditions that prevent them
from taking Abrocitinib.
All participants in this study will receive Abrocitinib as a tablet once daily. They can
take Abrocitinib and use medicated topical treatment for AD at the same time.
We will examine the experiences of patients receiving the study medicine. This will help
us determine if the study medicine is safe and helps in treating AD.
Participants will take part in this study for 24 months. During this time, they will
visit the study clinic about 5 times (about 1 time every 4 to 6 months).
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| HIA BEGIN | Contact (sur clinicalTrials) | ||||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Ch William Morey - 71100 - Chalon Sur Saone - France | Contact (sur clinicalTrials) | ||||
| CHU Amiens-Picardie - Site Nord - 80080 - Amiens - Somme - France | Contact (sur clinicalTrials) | ||||
| CHU Besancon - Hopital Jean Minjoz - 25000 - Besancon - France | Contact (sur clinicalTrials) | ||||
| CHU Clermont Ferrand - Hopital Gabriel Montpied - 63000 - Clermont-Ferrand - France | Contact (sur clinicalTrials) | ||||
| Chu Dijon - 21000 - Dijon - France | Contact (sur clinicalTrials) | ||||
| Chu Estaing - 63003 - Clermont Ferrand Cedex 1 - France | Contact (sur clinicalTrials) | ||||
| CHU Lyon Sud - 69495 - Pierre-Bénite - France | Contact (sur clinicalTrials) | ||||
| Hopital Claude Huriez - 59000 - Lille - France | Contact (sur clinicalTrials) | ||||
| Hopital Saint Louis (APHP) - Service Hematologic Senior - 75475 - Paris CEDEX 10 - France | Contact (sur clinicalTrials) | ||||
Critères
Tous
Inclusion Criteria:
- Patients older than 18 years of age at inclusion.
- Patients with clinical diagnosis of moderate-to-severe chronic atopic dermatitis
(also referred to as atopic eczema) at inclusion according to the investigator and
eligible for abrocitinib according to its marketing approval.
- Patients that have been informed of the study procedures and have signed the
consent.
- Patients older than 18 years of age at inclusion.
- Patients with clinical diagnosis of moderate-to-severe chronic atopic dermatitis
(also referred to as atopic eczema) at inclusion according to the investigator and
eligible for abrocitinib according to its marketing approval.
- Patients that have been informed of the study procedures and have signed the
consent.
- Patients for whom abrocitinib is contraindicated.
- Patients unable to follow and respect the study procedures and judged inapt to
respond to the questions required for the study due to linguistical, psychological,
social, or geographical reasons.
- Patients not affiliated to the French social security system.
- Patients deprived of liberty, under guardianship, or unable to provide oral consent.
- Patients participating in a clinical study assessing a medicinal treatment (patients
can participate in registries and observatories).